A. Jacolot et al., Pharmacokinetics of cefpirome during the posttraumatic systemic inflammatory response syndrome, INTEN CAR M, 25(5), 1999, pp. 486-491
Objective:To determine the pharmacokinetic parameters of cefpirome, a new s
o-called fourth-generation cephalosporin, in previously healthy trauma pati
ents with posttraumatic systemic inflammatory response syndrome (SIRS) and
to compare them to parameters obtained in matched, healthy volunteers.
Design: A prospective study.
Setting: 12-bed surgical intensive care unit in a university hospital.
Patients: 9 severe [Injury Severity Score, median (range) 29 (16-50)] traum
a patients on mechanical ventilation with proven or suspected cefpirome-sus
ceptible nosocomial infection, with no renal or hepatic failure, and health
y volunteers matched for age ( +/- 5 years), sex, and body surface area (+/
- 10%) were enrolled. All were men.
Interventions: Cefpirome (2 g twice daily) was continuously infused over a
0.5 h period alone or concomitantly with ciprofloxacin (400 mg over 1 h, tw
ice daily).
Measurements and main results: Antibiotic concentrations in plasma were mea
sured by high-performance liquid chromatography; their pharmacokinetic para
meters were evaluated at 12 time points after the first drug administration
using a noncompartmental model. Cefpirome pharmacokinetic parameters for t
he two groups were similar despite a wider variation for trauma patients, S
pecifically, the median (range) time during which the cefpirome concentrati
on in plasma remained over 4 mg/l (corresponding to the French lower cutoff
determining cefpirome susceptibility) was 9.5 (7- > 12) and 9 (8-12) h for
trauma patients and healthy volunteers, respectively. In the group of five
patients receiving combined antibiotic therapy, the interindividual variab
ility of pharmacokinetics was wider for ciprofloxacin than for cefpirome,
Conclusion: No major pharmacokinetic modification was noted when cefpirome
was given to trauma patients with posttraumatic SIRS without significant or
gan failure, indicating that no dosage adjustment seems required in this po
pulation. However, larger studies including determination of antibiotic lev
els in tissues are warranted to confirm these results.